L-HSA-DOXO

**L-HSA-DOXO** is an investigational liver-targeted doxorubicin conjugate in which doxorubicin is covalently linked to lactosaminated human serum albumin through an acid-sensitive hydrazone-containing linker. Lactosamine residues promote receptor-mediated hepatic uptake, including uptake by asialoglycoprotein receptor-expressing hepatocellular carcinoma cells; intracellular release of doxorubicin then produces anthracycline cytotoxicity through DNA intercalation and topoisomerase II inhibition. It has shown antitumor activity, improved hepatic tumor drug accumulation, and survival benefit versus free doxorubicin in chemically induced rat hepatocellular carcinoma models, but no marketed product, INN, or human clinical-development program was identified. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27825923/))

Other names

doxorubicin coupled to lactosaminated human albuminlactosaminated albumin conjugate of doxorubicinlactosaminated human albumin-doxorubicin conjugate